Targeted therapeutics drive the US cancer treatment market
Personalised therapeutics that match intervention to the type, location, morphology and other tumour- and patient-specific criteria account for two-thirds of the 400 cancer medicines in development, according to a new report from California-based MedMarket Diligence.
Personalised therapeutics that match intervention to the type, location, morphology and other tumour- and patient-specific criteria account for two-thirds of the 400 cancer medicines in development, according to a new report from California-based MedMarket Diligence.
Immunotherapies, antisense therapies and gene therapies have advanced to trials and are revealing exciting benefits as standalone or adjunctive therapeutics, it says.
'While the vast bulk of the market for cancer therapeutics continues to be in pharmaceuticals, the level of activity and sophistication in the development of biotherapeutics is evidence of the promise in what most of these provide, and that's their precision as targeted therapeutics,' suggests Patrick Driscoll, president of MedMarket Diligence.
This heightened ability to more precisely destroy or arrest each tumour without causing collateral tissue damage is expected to result in an annual market growth rate in excess of 30% for these technologies within the next few years, according to Driscoll.
But advances in cancer treatment are not limited to developments in biotherapeutics, the report says. Technologies that have already had an impact on the market will demonstrate equally strong growth. These include microdelivery systems, energy-based tissue ablation systems, brachytherapy and others. Another significant trend in cancer therapy is the use of multi-ple modalities to enhance further the specificity of each treatment.
The MedMarket Diligence report analyses current and emerging products, technologies and markets involved in oncology encompassing detection and diagnostic systems, drug delivery devices, chemotherapy, ablation, orthotics and prosthetics, radiation therapy, biological therapies, pharmaceuticals, transplantation and emerging technologies. It provides a forecast to 2013 of the US markets for these technologies, with particular emphasis on the market impact of new technologies through the coming decade and profiles some 80 key companies in this industry, detailing their current products, current market position and products under development.